President Donald Trump signed an executive order aimed at expanding access to psychedelic drugs for treating mental health conditions like depression and anxiety.

The order directs $50 million in federal funding and instructs the Food and Drug Administration to fast-track reviews of substances such as psilocybin and ibogaine.

Officials said the goal is to address rising mental health issues, including suicide and severe depression, affecting millions of Americans.

The initiative also involves expedited review programs that could significantly shorten approval timelines for these treatments, NPR has reported.

While supporters cite promising research, psychedelics remain federally classified as highly restricted drugs, and their medical use is still under scientific and regulatory evaluation.